BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

757 related articles for article (PubMed ID: 22331219)

  • 1. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.
    Haug AR; Tiega Donfack BP; Trumm C; Zech CJ; Michl M; Laubender RP; Uebleis C; Bartenstein P; Heinemann V; Hacker M
    J Nucl Med; 2012 Mar; 53(3):371-7. PubMed ID: 22331219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.
    Fendler WP; Philippe Tiega DB; Ilhan H; Paprottka PM; Heinemann V; Jakobs TF; Bartenstein P; Hacker M; Haug AR
    J Nucl Med; 2013 Aug; 54(8):1202-8. PubMed ID: 23729697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization.
    Piduru SM; Schuster DM; Barron BJ; Dhanasekaran R; Lawson DH; Kim HS
    J Vasc Interv Radiol; 2012 Jul; 23(7):943-8. PubMed ID: 22609292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres.
    Haug AR; Heinemann V; Bruns CJ; Hoffmann R; Jakobs T; Bartenstein P; Hacker M
    Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1037-45. PubMed ID: 21308371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, Efficacy, and Prognostic Factors After Radioembolization of Hepatic Metastases from Breast Cancer: A Large Single-Center Experience in 81 Patients.
    Fendler WP; Lechner H; Todica A; Paprottka KJ; Paprottka PM; Jakobs TF; Michl M; Bartenstein P; Lehner S; Haug AR
    J Nucl Med; 2016 Apr; 57(4):517-23. PubMed ID: 26742710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study.
    Ueda S; Tsuda H; Saeki T; Omata J; Osaki A; Shigekawa T; Ishida J; Tamura K; Abe Y; Moriya T; Yamamoto J
    Breast Cancer; 2011 Oct; 18(4):299-308. PubMed ID: 20617404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative dosimetry for yttrium-90 radionuclide therapy: tumor dose predicts fluorodeoxyglucose positron emission tomography response in hepatic metastatic melanoma.
    Eaton BR; Kim HS; Schreibmann E; Schuster DM; Galt JR; Barron B; Kim S; Liu Y; Landry J; Fox T
    J Vasc Interv Radiol; 2014 Feb; 25(2):288-95. PubMed ID: 24269792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Yttrium-90 radioembolization in patients with unresectable liver metastases: determining the factors that lead to treatment efficacy.
    Gunduz S; Ozgur O; Bozcuk H; Coşkun HS; Ozdogan M; Erkilic M; Sindel T; Yldlzs A; Ylmaz S; Boz A; Aydin F; Karayalçin B; Savas B
    Hepatogastroenterology; 2014 Sep; 61(134):1529-34. PubMed ID: 25436337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of quantitative parameters of 18F-FDG PET/CT in the evaluation of response to internal radiation therapy with yttrium-90 in patients with liver metastases of colorectal cancer.
    Soydal C; Kucuk ON; Gecim EI; Bilgic S; Elhan AH
    Nucl Med Commun; 2013 May; 34(5):501-6. PubMed ID: 23478586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.
    Huang WY; Kao CH; Huang WS; Chen CM; Chang LP; Lee MS; Chao HL; Chiu CH; Lo CH; Jen YM
    J Nucl Med; 2013 Oct; 54(10):1710-6. PubMed ID: 23970365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer.
    Sabet A; Meyer C; Aouf A; Sabet A; Ghamari S; Pieper CC; Mayer K; Biersack HJ; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):370-6. PubMed ID: 25351506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.
    Groheux D; Hatt M; Hindié E; Giacchetti S; de Cremoux P; Lehmann-Che J; Martineau A; Marty M; Cuvier C; Cheze-Le Rest C; de Roquancourt A; Visvikis D; Espié M
    Cancer; 2013 Jun; 119(11):1960-8. PubMed ID: 23504954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival in patients with hepatocellular carcinoma treated with 90Y-microsphere radioembolization. Prediction by 18F-FDG PET.
    Sabet A; Ahmadzadehfar H; Bruhman J; Sabet A; Meyer C; Wasmuth JC; Pieper CC; Biersack HJ; Ezziddin S
    Nuklearmedizin; 2014; 53(2):39-45. PubMed ID: 24777354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria.
    Zerizer I; Al-Nahhas A; Towey D; Tait P; Ariff B; Wasan H; Hatice G; Habib N; Barwick T
    Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1391-9. PubMed ID: 22644713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early metabolic response assessment of breast cancer liver metastases: 4-week posttreatment FDG PET predicts survival after 90Y microsphere radioembolization.
    Sabet A; Ries M; Al-Khalaf Y; Meyer C; Rudlowski C; Simon B; Khreish F; Ezziddin S
    Nuklearmedizin; 2019 Jun; 58(3):242-248. PubMed ID: 31167272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F]fluorodeoxyglucose positron emission tomographic imaging.
    Wong CY; Qing F; Savin M; Campbell J; Gates VL; Sherpa KM; Lewandowski RJ; Nagle C; Salem R
    J Vasc Interv Radiol; 2005 Aug; 16(8):1101-6. PubMed ID: 16105922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients.
    Klingenstein A; Haug AR; Zech CJ; Schaller UC
    Cardiovasc Intervent Radiol; 2013 Feb; 36(1):158-65. PubMed ID: 22526099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDG-PET-CT and whole-body MRI for triage in patients planned for radioembolisation therapy.
    Schmidt GP; Paprottka P; Jakobs TF; Hoffmann RT; Baur-Melnyk A; Haug A; Notohamiprodjo M; Baur-Melnyk A; Nikolaou K; Reiser MF; Rist C
    Eur J Radiol; 2012 Mar; 81(3):e269-76. PubMed ID: 21398060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG PET/CT as a prognostic test after 90Y radioembolization in patients with metastatic hepatic disease.
    Zalom M; Yu R; Friedman M; Bresee C; Waxman A
    Clin Nucl Med; 2012 Sep; 37(9):862-5. PubMed ID: 22889775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization.
    Abuodeh Y; Naghavi AO; Ahmed KA; Venkat PS; Kim Y; Kis B; Choi J; Biebel B; Sweeney J; Anaya DA; Kim R; Malafa M; Frakes JM; Hoffe SE; El-Haddad G
    World J Gastroenterol; 2016 Dec; 22(47):10406-10414. PubMed ID: 28058021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.